Jin Kumagai, Masahiro Kiuchi, Kota Kokubo, Hiroyuki Yagyu, Masahiro Nemoto, Kaori Tsuji, Ken Nagahata, Atsushi Sasaki, Takahisa Hishiya, Miki Onoue, Rie Shinmi, Yuri Sonobe, Tomohisa Iinuma, Syuji Yonekura, Jun Shinga, Toyoyuki Hanazawa, Haruhiko Koseki, Toshinori Nakayama, Koutaro Yokote, Kiyoshi Hirahara
Proceedings of the National Academy of Sciences of the United States of America 120(49) e2302903120 2023年12月5日 査読有り筆頭著者
Uncontrolled type 2 immunity by type 2 helper T (Th2) cells causes intractable allergic diseases; however, whether the interaction of CD4+ T cells shapes the pathophysiology of allergic diseases remains unclear. We identified a subset of Th2 cells that produced the serine proteases granzyme A and B early in differentiation. Granzymes cleave protease-activated receptor (Par)-1 and induce phosphorylation of p38 mitogen-activated protein kinase (MAPK), resulting in the enhanced production of IL-5 and IL-13 in both mouse and human Th2 cells. Ubiquitin-specific protease 7 (USP7) regulates IL-4-induced phosphorylation of STAT3, resulting in granzyme production during Th2 cell differentiation. Genetic deletion of Usp7 or Gzma and pharmacological blockade of granzyme B ameliorated allergic airway inflammation. Furthermore, PAR-1+ and granzyme+ Th2 cells were colocalized in nasal polyps from patients with eosinophilic chronic rhinosinusitis. Thus, the USP7-STAT3-granzymes-Par-1 pathway is a potential therapeutic target for intractable allergic diseases.